Japan: Market Entry, Experiences, and Key Opportunities
The Japan market is often viewed as a difficult market for drug developers, but recent reforms and strategic advantages aimed at accelerating development and commercialization timelines have changed the way biotech and pharma operate in this important global market.
Learn more about leveraging the Japan market’s advantages and navigating its development dynamics, with insights from Citeline and CMIC.
- Common – but outdated – misconceptions about Japan’s restrictiveness for drug developers
- Updated information on key, favorable regulatory reforms making it easier to do business in Japan
- Understanding Japan’s important advantages for accelerating clinical research timelines, reimbursement, and more
- Navigating Japan’s clinical trial environment with the critical help of an experienced CRO partner
Roundtable Panelists:
- Dr. DeKuan Chang, Senior Director, Program Team Lead, BeiGene
- Dr. Melody Dai, Founder & CEO, Global Molecular Solutions; Senior Leader in Regulatory Affairs
- Masashi Fukuari, Director, Business Strategy, OrphanPacific (CMIC Group)
- Dr. Taruho Kuroda, CEO, BlackFields Consulting
- Takeshi Sakata, Senior Consultant, Clinical Science Group, Drugs & Regenerative Medicine Consulting Department, CMIC
Moderator:
- Dr. Andrew Warmington, Manufacturing Editor, Citeline
